Cell and Gene Commercialization
-
A Look At siRNA & Market Trends
1/3/2024
Small interfering RNA (siRNA) is a class of molecules that play a crucial role in the regulation of gene expression. This article shares how siRNA functions as well as new market research for the field.
-
How Well-Supported Is The Current Technology Vendor Space?
1/2/2024
Take a look at the current cell and gene technological landscape, along with how well industry needs are being met and where there is room for improvement.
-
How Automation Improves Safety And Efficacy Of Source Material Collection
12/13/2023
Implementing more automated workflows in cell therapy manufacturing can serve to minimize open processes and manual touchpoints, increasing reproducibility and improving traceability.
-
Preparing Your CAR-T Therapy For Phase 2 Trials
12/6/2023
AffyImmune CEO, Matt Britz, talks about what’s next for the company as it prepares its lead CAR-T candidate for Phase 2 trials — from clinical strategy to selecting a CDMO and the headache of tech transfers.
-
Gene Therapy Deals, Collaborations, & Partnerships With Astellas' Richard Wilson
11/21/2023
Astellas' Richard Wilson is Erin Harris' guest on Cell & Gene: The Podcast to discuss deals and collaborations in gene therapy.
-
Driving Down COGS: Leveraging Automation Technologies And Mitigating Risk
11/17/2023
The technologies aimed at automating and standardizing cell therapy production are poised to offer advanced therapy companies and CDMOs process-level improvements that streamline and accelerate workflows.
-
A Multi-Vector Perspective: LVV And AAV Development And Manufacturing
11/17/2023
Finding a CDMO partner with the resources and expertise to achieve efficient and scalable manufacturing is a key step in achieving the scalable manufacture of safe, effective AAV gene therapies.
-
3 Steps For Cell & Gene Therapy Medical Affairs Teams To Provide Strategic Value
11/15/2023
Historically, medical affairs has been seen as more of a resource, as the group that answers complex scientific questions. However, medical affairs teams at cell and gene therapy companies must be more strategic.
-
Driving Down COGS: Breaking Down Automated Manufacturing
11/7/2023
While working to optimize discrete process steps is important, achieving CAR-T scalability requires finding ways to perform some steps concurrently, necessitating a more holistic approach to innovation.
-
Important Ethical Questions Concerning CGTs
11/3/2023
This is a summary of Alliance For Regenerative Medicine's panel discussion, "The Importance Of Ethics In Gene And Cell Therapy," from this year's Meeting On The Mesa.